One in a billion
iCellate Medical offers services in liquid biopsy, to detect, isolate and analyze circulating tumor cells (CTCs), circulating tumor DNA and germ-line DNA, from normal blood samples. In our ISO 15189 certified lab, we perform liquid biopsy analysis with our proprietary isolation system IsoPic™ (CTC) and related downstream verification tests, such as NGS sequencing.
CTCs are rare, a few cells among tens of billions of normal blood cells, and therefore very difficult to find. IsoPic™ uses conserved biomechanical properties to capture the CTCs from the blood and does not rely on conventional biomarkers that are known to often miss some of the unpredictably variable cancer cells. iCellate’s technique has a very high sensitivity, IsoPic™ can find a CTC cell with a probability of 9 out of 10 (90%).
With iCellate’s techniques in combination with genetic sequencing, cancer can be detected at an early stage, but also used to pinpoint the exact molecular defects driving each patient’s individual cancer, and therefore also follow the molecular development of the disease, almost in real time.
90% Capture Rate
In a typical clinical blood sample with 10 spiked tumor cells (MCF-7, HeLa or Sarcoma) among 10s of billions of normal blood cells, iCellate’s technique can identify 9 out of 10 of the CTCs (90% median capture rate). That is more than adequate to acquire a relevant sample to analyze the spreading cancer cells.
1 10 ml blood draw
2 CTC Isolation
3 LCM microscopy
4 Genetic sequencing
iCellate, as one of very few companies in the World, offers a complete range of label-free CTC analysis from isolation to genetic sequencing in our own laboratory. The freshness of the blood sample is key, with iCellate’s solution blood can accurately be analyzed within 48h.
What is a circulating tumor cell (CTC)?
Cancer is a broad range of diseases that results in accumulation of abnormal cells (i.e. a tumor). Cancer originates from a single abnormal cell that grows into a primary tumor from which individual cells can spread through the lymphatic system or the blood stream to distant parts of the body and form metastases.The cells that spread the disease to distant organs, where they form metastases, are the circulating tumor cells (CTCs). Metastases are almost always associated with fatal disease.
Cancer cells migrate into the lymphatic and blood circulation systems co-opting them as a transportation vehicle to ultimately metastasize to other parts of the body. Once in the blood, the clear majority of the circulating tumor cells fortunately die causing fewer metastases than otherwise (a phenomenon known as metastatic inefficiency), but a few survive. A few of those also attach at distant organs where they may exit the circulation and migrate further into the distant organ site where they may settle down. A few of those dispersed cells may start to grow to ultimately form new spread tumors, metastases. Knowing the numbers and genetic properties of the spreading tumor cells is key to predicting how to treat them.